Please assess the completion status of the following clinical trial:

Trial Title: STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed SCLC~* Stage IV disease~* Performance status ECOG 0-2~* Life expectancy \>8 weeks~* Age 18 or over~* Willing and able to give informed consent~* Patient considered able to tolerate chemotherapy~* Adequate renal function - defined by GFR ≥50mL/min as measured by EDTA or C\&G~* Adequate bone marrow reserve: Absolute neutrophil count ≥1.5 x 109/L, haemoglobin ≥90 g/L, platelet count ≥100 x 109/L~* Negative pregnancy test for WCBP~* Highly effective contraception is mandatory for all patients of reproductive potential~* At least one site of measurable disease (target lesion) for RECIST 1.1 evaluation~* Hypersensitivity or history of severe allergic reaction to any of the IMPs~* Able to swallow medication~Exclusion Criteria:~* Mixed cell histology (i.e. NSCLC and SCLC)~* Prior macular degeneration or diabetic retinopathy~* History of glaucoma~* Patients with abnormal LFTs (ALP, ALT/AST\*) that are ≥3 x ULN (≥5 x ULN for patients with liver metastases)~* Patients with abnormal bilirubin levels that are ≥1.5 x ULN~* Prior treatment for this disease e.g. chemotherapy, surgery, radiotherapy (except palliative radiotherapy to bone metastases)~* Documented side effects to chloroquine or related agents~* Treatment with chloroquine or related agents within the last year prior to randomisation~* Evidence of significant medical condition or laboratory finding which, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial~* Previous medical history of prolonged QT interval~* A history of prior malignant tumour, unless the patient has been without evidence of disease for at least 3 years or the tumour was a non-melanoma skin tumour or early cervical cancer~* Patients with symptomatic brain metastases~* Women who are breastfeeding~* Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs e.g. phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine~* Patients who are unable to have their digoxin levels regularly monitored~  * if both ALT and AST performed then both need to be recorded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: ACTIVE_COMPARATOR): * IV carboplatin AUC5 (area under curve) on Day1~* IV etoposide 120mg/m2 Day 1, followed by oral etoposide 100mg BD (twice daily) on Day 2 and Day 3
- Investigational Arm (Type: EXPERIMENTAL): * IV gemcitabine 1200mg/m2 on Day 1 and Day 8~* IV carboplatin AUC5 on Day 1~* Oral HCQ will be taken at a dose of 400mg BD from day 1 of cycle 1 (maximum of 30 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).